Eli Lilly
-
‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’sThis is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved lecanemab, commercially known as Leqembi, in October 2025.CanadaMay 4
-
FDA approves new Alzheimer’s drug that slows memory declineA key differentiating factor for donanemab is the drug's finite dosing, which allows patients to stop taking the treatment once brain scans no longer show amyloid plaques.HealthJul 3, 2024
-
Decision on Eli Lilly’s Alzheimer’s drug delayed by U.S. FDAThe U.S. Food and Drug Administration has delayed its decision on Eli Lilly's LLY.N experimental treatment for early Alzheimer's disease.HealthMar 8, 2024
![]()
-
Eli Lilly’s new version of diabetes drug Mounjaro approved for weight loss by FDAA new version of the popular diabetes treatment Mounjaro from Eli Lilly can be sold as a weight-loss drug, U.S. regulators announced Wednesday.HealthNov 8, 2023
![]()
-
Alzheimer’s drug slows progression in patients. It may soon be approved in U.S.Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.HealthJul 17, 2023
![]()
-
No insulin price cut coming for Canada despite U.S. slashes, Eli Lilly saysEli Lilly and Co. announced Wednesday that it will cut prices for some of its most commonly prescribed insulin products in the United States.CanadaMar 3, 2023
![]()
-
Drugmaker Eli Lilly slashes prices, will offer $35 insulin in U.S. pharmaciesIn addition to slashing some drug prices by 70 per cent, Eli Lilly also promised to expand an existing program that caps some insulin products at $50.U.S. NewsMar 1, 2023
![]()
-
FDA authorizes new antibody drug that targets Omicron COVID-19 variantThe Food and Drug Administration said it cleared the Eli Lilly drug for adults and adolescent patients with mild-to-moderate cases of COVID-19.WorldFeb 11, 2022
![]()
-
U.S. limits use of Regeneron, Eli Lilly COVID-19 antibody treatments amid Omicron spreadLast month, the U.S. had paused the distribution of Regeneron and Lilly's treatments and said the halt would continue until new data emerges on their efficacy against Omicron.HealthJan 24, 2022
![]()
-
Standard drugs used to fight COVID-19 may not work against Omicron: U.S. doctorsThe shrinking toolbox of treatments is a painful reminder that COVID-19 still has the upper hand in the U.S., even with more than 200 million Americans fully vaccinated.HealthDec 19, 2021
![]()
